Top

Published in:

01-02-2019 | Original Communication

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

Authors: E. D’Amico, A. Zanghì, M. Sciandra, G. Borriello, G. Callari, A. Gallo, G. Salemi, S. Cottone, M. Buccafusca, P. Valentino, R. B. Bossio, L. M. E. Grimaldi, C. Pozzilli, G. Tedeschi, M. Zappia, F. Patti

Published in: Journal of Neurology | Issue 2/2019

Abstract

Background

Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS).

Objectives

We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF.

Materials and methods

A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days.

Results

A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TRF and DMF showed similar discontinuation rates. The analysis of predictors with Cox regression model showed differences between the two groups (p for log-rank test = 0.007); male gender [HR 2.21 (1.00–4.90); p = 0.01] and the number of previous switches [HR 1.47 (1.16–1.86); p = 0.01] were associated with higher hazard of discontinuation in the DMF group.

Conclusions

In a real-world setting, pwRRMS on TRF and DMF had similar discontinuation rates over 24 months. Male pwRRMS on DMF with a previous history of therapeutic failure are at more risk of discontinuation therapy.

Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple Sclerosis. N Engl J Med 378(2):169–180CrossRefPubMed

D’Amico E, Zanghi A, Leone C, Tumani H, Patti F (2016) Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review of current evidence and future needs. Drug Saf 39(12):1163–1174CrossRefPubMed

D’Amico E, Leone C, Caserta C, Patti F (2015) Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Rev Neurother 15(7):803–824CrossRefPubMed

D’Amico E, Patti F, Zanghi A, Zappia M (2016) A personalized approach in progressive multiple sclerosis: the current status of disease modifying therapies (DMTs) and future perspectives. Int J Mol Sci 17(10):1725CrossRefPubMedCentral

Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H et al (2011) Bridging the efficacy–effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov 10(7):495–506CrossRefPubMed

Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V (2017) Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Spec Pharm 23(8):844–852PubMed

Lattanzi S, Danni M, Taffi R, Cerqua R, Carlini G, Pulcini A et al (2017) Persistence to oral disease-modifying therapies in multiple sclerosis patients. J Neurol 264(11):2325–2329CrossRefPubMed

Eriksson I, Cars T, Piehl F, Malmstrom RE, Wettermark B, von Euler M (2018) Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. Eur J Clin Pharmacol 74(2):219–226CrossRefPubMed

Ferraro D, Camera V, Baldi E, Vacchiano V, Curti E, Guareschi A et al (2018) First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence. Curr Med Res Opin 1:1–5

10.

Sejbaek T, Nybo M, Petersen T, Illes Z (2018) Real-life persistence and tolerability with dimethyl fumarate. Mult Scler Relat Disord 24:42–46CrossRefPubMed

11.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S et al (2018) Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract 8(4):292–301CrossRefPubMedPubMedCentral

12.

Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S et al (2018) Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol 265(8):1850–1859CrossRefPubMed

13.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedPubMedCentral

14.

D’Amico E, Zanghì A, Callari G, Borriello G, Gallo A, Graziano G et al (2018) Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting multiple sclerosis: an Italian real-word multicenter experience. Ther Adv Neurol Disord 11:1756286418796404CrossRef

15.

https://www.ema.europa.eu/...guideline/guideline-good-pharmacovigilance-practices-gv. Accessed Oct 2018

16.

Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP et al (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13(3):247–256CrossRefPubMed

17.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097CrossRef

18.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107CrossRefPubMed

19.

O’Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP et al (2016) Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology 86(10):920–930CrossRefPubMedPubMedCentral

20.

Lugaresi A, Rottoli MR, Patti F (2014) Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother 14(9):1029–1042CrossRefPubMed

21.

Theodore Phillips J, Erwin AA, Agrella S, Kremenchutzky M, Kramer JF, Darkes MJ et al (2015) Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a Delphi study. Neurol Ther 4(2):137–146CrossRefPubMedPubMedCentral

22.

Ziemssen T, Kern R, Thomas K (2016) Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurol 16(1):124CrossRefPubMedPubMedCentral

Title: Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience
Authors: E. D’Amico
A. Zanghì
M. Sciandra
G. Borriello
G. Callari
A. Gallo
G. Salemi
S. Cottone
M. Buccafusca
P. Valentino
R. B. Bossio
L. M. E. Grimaldi
C. Pozzilli
G. Tedeschi
M. Zappia
F. Patti
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 2/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-9144-9

At a glance: The STEP trials

Springer Medicine

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

Abstract

Background

Objectives

Materials and methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objectives

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Cannabis use in myotonic dystrophy patients in Germany and USA: a pilot survey

Patient characteristics and outcome associations in AMPA receptor encephalitis

Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome

ANO10 mutational screening in recessive ataxia: genetic findings and refinement of the clinical phenotype

Limb girdle muscular dystrophy D3 HNRNPDL related in a Chinese family with distal muscle weakness caused by a mutation in the prion-like domain

Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy